搜索

联系我们 / CONTACT US

地址:福州市仓山区进步路25号


 

0591-83441193

Copyright © 2022 福建省微生物研究所 版权所有 网站建设:中企动力福州  闽ICP备10006540 

地址:  福州市仓山区进步路25号    办公室电话:  0591-83441193、83476798  

科技管理科电话:  0591-83309157、83586273       传真:  0591-83441193   邮箱:  fim_cn@163.com

福建省微生物研究所

友情链接:  

用微信扫一扫

微信号
>
>
>
FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus ofHsp90 and disrupt

FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus ofHsp90 and disrupt

作者:
来源:
浏览量
【摘要】:
{Author}:HuangW, YeM, ZhangLR, WuQD, ZhangM, XuJH, ZhengW.{Year}:2014{Title}:FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus ofHsp90 and di

{Author}:Huang W, Ye M, Zhang LR, Wu QD, Zhang M, Xu JH, Zheng W.

{Year}:2014

{Title}:FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus ofHsp90 and disrupting Hsp90-Cdc37 complex formation.

{Journal}:Mol Cancer.

{Volume}: Online

{Pages}:online

{Keywords}:FW-04-806, Hsp90, Cdc37, HER2, Breast cancer

{Abstract}:

BACKGROUND:

Heat shock protein 90 (Hsp90) is a promising therapeutic target and inhibition of Hsp90 will presumably result in suppression of multiple signaling pathways. FW-04-806, a bis-oxazolyl macrolide compound extracted from China-native Streptomyces FIM-04-806, was reported to be identical in structure to the polyketide Conglobatin.

METHODS:

We adopted the methods of chemproteomics, computational docking, immunoprecipitation, siRNA gene knock down, Quantitative Real-time PCR and xenograft models on the research of FW-04-806 antitumor mechanism, through the HER2-overexpressing breast cancer SKBR3 and HER2-underexpressing breast cancer MCF-7 cell line.

RESULTS:

We have verified the direct binding of FW-04-806 to the N-terminal domain of Hsp90 and found that FW-04-806 inhibits Hsp90/cell division cycle protein 37 (Cdc37) chaperone/co-chaperone interactions, but does not affect ATP-binding capability of Hsp90, thereby leading to the degradation of multiple Hsp90 client proteins via the proteasome pathway. In breast cancer cell lines, FW-04-806 inhibits cell proliferation, caused G2/M cell cycle arrest, induced apoptosis, and downregulated Hsp90 client proteins HER2, Akt, Raf-1 and their phosphorylated forms (p-HER2, p-Akt) in a dose and time-dependent manner. Importantly, FW-04-806 displays a better anti-tumor effect in HER2-overexpressed SKBR3 tumor xenograft model than in HER2-underexpressed MCF-7 model. The result is consistent with cell proliferation assay and in vitro apoptosis assay applied for SKBR-3 and MCF-7. Furthermore, FW-04-806 has a favorable toxicity profile.

CONCLUSIONS:

As a novel Hsp90 inhibitor, FW-04-806 binds to the N-terminal of Hsp90 and inhibits Hsp90/Cdc37 interaction, resulting in the disassociation of Hsp90/Cdc37/client complexes and the degradation of Hsp90 client proteins. FW-04-806 displays promising antitumor activity against breast cancer cells both in vitro and in vivo, especially for HER2-overexpressed breast cancer cells.

科研成果

SCIENTIFIC PAYOFFS

相关附件